Deep learning of pretreatment multiphase CT images for predicting response to lenvatinib and immune checkpoint inhibitors in unresectable hepatocellular carcinoma
Objectives: Combination therapy of lenvatinib and immune checkpoint inhibitors (CLICI) has emerged as a promising approach for managing unresectable hepatocellular carcinoma (HCC). However, the response to such treatment is observed in only a subset of patients, underscoring the pressing need for re...
Saved in:
| Main Authors: | Nan-Qing Liao, Zhu-Jian Deng, Wei Wei, Jia-Hui Lu, Min-Jun Li, Liang Ma, Qing-Feng Chen, Jian-Hong Zhong |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-12-01
|
| Series: | Computational and Structural Biotechnology Journal |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2001037024000849 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Lenvatinib and immune-checkpoint inhibitors in hepatocellular carcinoma: mechanistic insights, clinical efficacy, and future perspectives
by: Yuhang Chen, et al.
Published: (2024-12-01) -
Efficacy and safety of atezolizumab–bevacizumab vs pembrolizumab-lenvatinib in unresectable hepatocellular carcinoma: a retrospective, cohort study
by: Zili Hu, et al.
Published: (2024-11-01) -
Lenvatinib Therapy in Patients with Unresectable Hepatocellular Carcinoma in Real Clinical Practice
by: V. V. Petkau, et al.
Published: (2022-12-01) -
Geriatric nutritional risk index and newly developed scoring system as prognosis prediction for unresectable hepatocellular carcinoma patients treated with lenvatinib
by: Hideko Ohama, et al.
Published: (2025-01-01) -
Lenvatinib versus sorafenib as second-line therapy following progression on atezolizumab–bevacizumab in patients with unresectable hepatocellular carcinoma: a multicenter retrospective study from Korea and Japan
by: Jaekyung Cheon, et al.
Published: (2025-01-01)